Postmarket Study Published on Elixir Medical's DESolve Bioresorbable Scaffold
November 27, 2018—Twelve-month results from the multicenter postmarket clinical follow-up study of the DESolve novolimus‐eluting bioresorbable coronary scaffold system (Elixir Medical Corporation) were published by Holger Nef, MD, et al in Catheterization and Cardiovascular Interventions (2018;92:1021–1027). The investigators concluded that the DESolve bioresorbable scaffold (BRS) is a safe and effective treatment for coronary lesions in patients with stable coronary artery disease.
According to the investigators, the DESolve BRS combines a poly‐L‐lactide–based backbone with a biodegradable polylactide‐based polymer and novolimus, a macrocyclic lactone mTOR inhibitor.
The study enrolled 102 patients (mean age, 62 years; 77.5% men) at 10 European sites. Investigators performed a comparison of baseline and postprocedural angiographic assessments. Additionally, they examined a device‐oriented composite endpoint (cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization) and rate of scaffold thrombosis at 12 months.
As reported in Catheterization and Cardiovascular Interventions, the device was successfully delivered and deployed in 98.2% (107/109) of the lesions, with two failures to cross the lesion. A total of 100 patients (109 lesions) were treated with the DESolve BRS. Postprocedural angiographic assessment indicated an in‐scaffold acute gain of 1.54 ± 0.44 mm, with a reduction in percent diameter stenosis from 61.00% ± 11.29% to 12.69% ± 0.44%.
At 12 months, the device‐oriented composite endpoint had occurred in 3% (3/100) of patients, with 1% (1/100) experiencing scaffold thrombosis and myocardial infarction and 3% (3/100) undergoing target lesion revascularization. There were no cardiac deaths.
Larger long‐term prospective studies are needed, advised the investigators in Catheterization and Cardiovascular Interventions.
advertisement
Featured Video
Patients have to trust that if I were in their shoes, I wouldn’t do anything differently.
Sponsored by Boston Scientific
Related Articles
Angiography-Based FFR: Reevaluating the Role of the Pressure Wire
Reviewing the nuances of coronary angiography–based FFR and results of initial validation studies.
By Kaneshka Masdjedi, MD; and Joost Daemen, MD, PhD
Case Report: Antiplatelet Therapy After Complex PCI in the Anticoagulated Patient
By Michael P. Savage, MD, FACC, FSCAI, FACP; David L. Fischman, MD, FACC, FACP; and Marguerite Davis, BS, RT(R), RCIS
Case Report: Antiplatelet Therapy After Complex PCI in the Anticoagulated Patient
By Michael P. Savage, MD, FACC, FSCAI, FACP; David L. Fischman, MD, FACC, FACP; and Marguerite Davis, BS, RT(R), RCIS
Case Report: The Safety of Drug-Eluting Stents in High Bleeding Risk Patients
When anatomically complex meets clinically complex.
By José Francisco Díaz Fernández, MD, FESC; and Santiago Camacho Freire, MD
Top 5 Articles From October 2018
CT Assessment Before TMVR
By Moderator: Dee Dee Wang, MD, FACC, FASE, FSCCT
Panel: Mayra Guerrero, MD; and Marco Barbanti, MD
Challenging Cases: What Would You Do?
By Ted E. Feldman, MD, MSCAI, FACC, FESC; and Shakeel A. Qureshi, MD, FRCP, FRCPCH
Peripheral Vascular Programs Could Improve Population Health and Grow Volumes
An overview of the steps involved in developing a PAD program to address this underserved patient population.
By Ginger Biesbrock, PA-C, MPH, MPAS, AACC; and Joel Sauer, MBA
Complicated Radial Access During Primary PCI
By Moderator: Pieter C. Smits, MD, PhD, FESC
Panel: Mohamed Abdel-Wahab, MD, FESC; Peter W. Danse, MD; and Valeria Paradies, MD
Planning for Transcatheter Aortic Valve Replacement
By Moderator: Mauricio G. Cohen, MD, FACC, FSCAI
Panel: Santiago Garcia, MD, FACC, FSCAI; William O’Neill, MD; and Molly Szerlip, MD, FACC, FSCAI
Top 5 from EVToday's Current Issue
Roundtable Discussion: Percutaneous AVF Creation in Practice
A multidisciplinary discussion on patient selection, achieving proficiency, procedural tips, and the importance of collaboration.
With John E. Aruny, MD; William C. Jennings, MD, FACS; Charmaine E. Lok, MD; and Aris Urbanes, MD
Understanding Benefits and Risks of Drug-Eluting Stents
Ongoing clinical studies will shed light on patient outcomes in real-world settings.
By Ian T. Meredith, MBBS, PhD, AM
Evaluation and Management of Chronic Thoracic Venous Obstructions
Clinical presentation, anatomic patterns of TCVO, and revascularization strategies.
By Brian Holly, MD; and Mark L. Lessne, MD
AV Access Covered Stent Clinical Trials: A Comparative Review
A status overview of six major clinical trials evaluating the use of covered stents in AV access treatment.
